Alkermes is set for growth by expanding LUMRYZ's use to treat idiopathic hypersomnia (IH) following successful Phase 3 trial results. This new indication could boost revenue by using existing sales infrastructure with minimal additional costs. Although Alkermes will pay a 10% royalty to Jazz Pharmaceuticals on non-narcolepsy LUMRYZ sales after March 2028, the financial opportunity remains significant. The company is valued at $57 per share, supported by LUMRYZ's expansion, EBITDA growth, and development in the sleep medicine sector.
Alkermes' expansion of LUMRYZ for idiopathic hypersomnia is the focus, with Pluang's health sector data providing context. As of Sep 26, 2026 19:02 WIB, among 100 priced health-sector US stocks on Pluang, 54 rose and 46 fell. Notable movers include BDX at USD 183.82 with a 1-day change of +2.56% and 100% sell order activity, ALNY at USD 255.96 with a +2.55% change and 100% buy order activity, and OSCR at USD 29.60 with a +2.53% change and 100% buy order activity.
electroCore is improving operationally and financially, driven by expanding its sales force and strong growth in its Quell Fibromyalgia product. The company aims for over 30% revenue growth by fiscal year 2026, gross margins above 85%, and positive a...
Ethereum's PeerDAS protocol, launched in December 2025, has successfully operated for nearly a year, revolutionizing data availability by allowing validators to confirm data without downloading full blocks. This innovation has reduced Layer 2 transac...
Bitcoin and stock markets show variable correlation influenced by macroeconomic conditions like global liquidity and risk appetite. Both tend to rise together when central banks ease financial conditions, favoring higher-risk assets like Bitcoin and ...
Fiserv is considered undervalued with a compelling buy rating due to its strong legacy client relationships, solid profitability, and strategic modernization efforts under its One Fiserv plan. Despite facing industry headwinds such as AI disruption, ...
The XRP Ledger has released a new software version, xrpld 3.4.1, which includes a fix for the batch amendment feature and broader stability improvements. The validator community coordinated to reset the activation vote for the batch amendment, allowi...
